SCHEMBL31247670

SCHEMBL31247670

Cc1cccc(Nc2cc(Nc3ccccc3C#N)nc(N)n2)n1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 4/20 0.48
▸ NUDT1 P36639 1/20 0.46
▸ BACE1 P56817 1/20 0.44
▸ GRM5 P41594 4/20 0.43
▸ AURKA O14965 2/20 0.43
▸ IRAK4 Q9NWZ3 1/20 0.43
▸ CYP1A2 P05177 1/20 0.42
▸ CYP2D6 P10635 1/20 0.42
▸ KMT2A Q03164 1/20 0.40
▸ JAK2 O60674 2/20 0.39
▸ JAK1 P23458 2/20 0.39
▸ TYK2 P29597 2/20 0.39
▸ JAK3 P52333 2/20 0.39
▸ MAP4K4 O95819 1/20 0.39
▸ GSK3B P49841 1/20 0.39
▸ NPC1 O15118 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ HSD11B1 P28845 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31247692 0.86 AURKA (0.47) SYKBACE1GRM5AURKAIRAK4
SCHEMBL31247764 0.77 JAK2 (0.55) SYKNUDT1AURKAKMT2AJAK2
SCHEMBL31247510 0.77 TYK2 (0.48) NUDT1CYP1A2CYP2D6JAK2JAK1
SCHEMBL15679618 0.76 SYK (0.46) SYKGRM5KMT2ANPC1RAB9A
SCHEMBL15649871 0.74 GRM5 (0.47) SYKGRM5KMT2AJAK2NPC1
SCHEMBL31247717 0.72 GRM5 (0.44) SYKGRM5AURKAIRAK4JAK2
SCHEMBL31247586 0.72 GRM5 (0.44) SYKGRM5AURKAIRAK4JAK2
SCHEMBL2779777 0.72 MEN1 (0.50) SYKGRM5CYP1A2CYP2D6KMT2A
SCHEMBL31247770 0.72 AURKA (0.43) SYKGRM5AURKAIRAK4KMT2A
SCHEMBL31247588 0.70 AURKA (0.55) AURKAIRAK4JAK2JAK1JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4719394-A2 INHIBITORS OF TYK2 Atomwise Inc. (US) 2026-04-08 — — EP disclosed
US-20260048051-A1 TREATMENT OF INFLAMMATORY BOWEL DISEASE ATOMWISE INC (US) 2026-02-19 — — US disclosed
US-12358904-B2 Inhibitors of TYK2 Atomwise Inc. (US) 2025-07-15 — — US disclosed
US-20240425484-A1 INHIBITORS OF TYK2 Atomwise Inc. 2024-12-26 — — US disclosed
US-20240417396-A1 INHIBITORS OF TYK2 Atomwise Inc. 2024-12-19 — — US disclosed
WO-2024250010-A2 INHIBITORS OF TYK2 Atomwise Inc. (US) 2024-12-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240417396-A1 INHIBITORS OF TYK2 TYK2, LCK, JAK2 SYK 11/4885NUDT1 4426/4885BACE1 3072/4885
US-20260048051-A1 TREATMENT OF INFLAMMATORY BOWEL DISEASE TYK2, FRK, DYRK2 SYK 33/4885NUDT1 4741/4885BACE1 3608/4885
US-12358904-B2 Inhibitors of TYK2 TYK2, LCK, JAK2 SYK 11/4885NUDT1 4426/4885BACE1 3072/4885
US-20240425484-A1 INHIBITORS OF TYK2 TYK2, LCK, JAK2 SYK 11/4885NUDT1 4426/4885BACE1 3072/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback